As semaglutide has gained popularity for weight loss, many patients wonder whether the medication poses risks to kidney healtha legitimate concern given the prevalence of chronic kidney disease in people with obesity and diabetes
Emerging enterococcus pore-forming toxins with MHC/HLA-I as receptors
Conflict of interest Author AA has received consulting fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz and Takeda
It feels like a boutique local clinic, not a cold online portal. Tirzepatide has been a game-changer for me
When it comes to Ozempic pens, refrigeration before the first use is mandatory
Natural Science Foundation of China (82304360)